1.Оганов Р.Г., Масленникова Г.Я. Сердечно-сосудистые заболевания в Российской Федерации во второй половине ХХ столетия: тенденции, возможные причины, перспективы. Кардиология. 2000; 6: 4–8.
2. European Society of Cardiology Guidelines on the management of stable angine pectoris: full text. 2006.
3. Neely J, Morgan H. Relationship between carbohydrate metabolism and energy balance of heart muscle. Ann Rev Physiol 1974; 36: 413.
4. Hansford R, Cohen I. Relative imortance of pyruvate dehydrogenase interconversion and feedback inhibition in the effect of fatty acids on pyruvate oxidation by rat heart mitochondria. Arch Biochem Byophis 1978; 191: 65–81.
5. Stanley W, Lopaschuk G, Hall J et al. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Cardiovasc Res 1997; 33: 243–57.
6. Teo K, Yusuf S, Furberg D et al. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA 1993; 270: 1589–95.
7. Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291: 309–16.
8. Scirica BM, Morrow DA, Hod H et al. Effect of Ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment-elevation acute coronary syndrome. Results from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial. Circulation 2007; 116: 1647–52.
9. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 Randomized Trial. JAMA 2007; 297: 1775–83.
10. Stone PH, Gratsiansky NA, Blokhin A et al. Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine. The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial. J Am Coll Cardiol 2006; 48: 566–75.
11. Morrow DA, Scirica BM, Chaitman BR et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009; 119: 2032–9.
12. Genissel P, Chordjania Y, Demolis JL et al. Eur J Drug Metabol Pharmacokin 2004; 29: 61–8.
13. Marzilli M, Klein W. Efficacy of tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trail. Coron Artery Dis 2003; 14 (2): 171–9.
14. Лупанов В.П., Васильева Н.Н., Малкина Т.А. и др. Опыт 3-месячного применения Предуктала в качестве антиангинального и антиишемического препарата у больных ИБС со стабильной стенокардией. Форум. ишем. бол. сердца. 2002; 6: 11–4.
15. Ben-Dor I, Battler A. Treatment of stable angina. Heart 2007; 93: 868–74.
16. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; 19 (4): CD003614.
17. Sellier P. The effects of trimetazidine on ergometric parameters in exercise-induced angina. Controlled multicenter double-blind versus placebo study. Arch Mal Coeur Vaiss 1986; 79 (9): 1331–6.
18. Gallet М. Сurrent concepts in cellular ischemia: role of trimetazidine. Ann Cardiol Angeiol (Paris) 1986; 35 (7, Pt 2): 459–62.
19. Detry JM, Seller P, Pennaforte S et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidin European Multicenter Study Group. Br J Clin Pharmacol 1994; 37 (2): 279–88.
20. Szwed H, Sadowski Z, Elikowski W et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II).TRIMetazidin in POLand. Eur Heart J 2001; 22 (24): 2267–74.
21. Michaelides AP, Spiropoulos K, Dimopoulos R et al. Antianginal efficacy of the combination of the trimetazidine – propranolol compared with isosorbide dinitrate – propranolol in patients with stable angina. Clin Drug Invest 1997; 13: 8–14.
22. McClellan KJ, Plosker GL. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. Drug 1999; 58 (1): 143–57.
23. Алмазов В.А., Шляхто Е.В., Нифонтов Е.М. и др. Антиишемическая эффективность триметазидина у больных со стабильной стенокардией. Кардиология. 2000; 6: 40–2.
24. Жиляев Е.В., Уржамова Т.В., Глазунов А.В. и др. Клинические аспекты применения триметазидина (Предуктала) в качестве антиангинального препарата. Тер. арх. 2004; 8: 20–3.
25. Бутина Е.К., Кокурина Е.В., Дмитриева Н.А., Бочкарева Е.В. Сниженная чувствительность к антиишемическому эффекту пропранолола и возможность ее коррекции у больных стабильной стенокардией. Тер. арх. 2002; 9: 16–21.
26. Szwed H, Sadowski Z, Pachocki R et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther 1999; 13 (3): 217–22.
27. Орлова Е.М., Миронова И.Ю.. Матвеева М.А. и др. Оценка антиангинального и антиишемического эффекта триметазидина и его влияния на перфузию миокарда у больных ишемической болезнью сердца. Кардиология. 2004; 9: 23–8.
28. Detry JM, Leclercq PJ. Trimetazidine European Multicenter Study versus propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol 1995; 76 (6): 8B–11.
29. Chazov EI, Lepakchin VK, Zharova EA et al. Trimetazidine in Angina Combination Therapy – the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005; 12 (1): 35–42.
30. Сыркин А.Л., Лепахин В.К., Фитилев С.Б. и др. Триметазидин при стабильной стенокардии напряжения у больных старше 65 лет. Исследование TRIMEР (Trimetazidine in Elderly People). Кардиология. 2002; 6: 24–31.
31. Бузиашвили Ю.И., Маколкин В.И., Осадчий К.К. и др. Влияние триметазидина на обратимую дисфункцию миокарда при ишемической болезни сердца. Кардиология. 1999; 6: 33–8.
32. Mody FV, Singh BN, Mohiuddin IH et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 1998; 82 (5A): 42K–49K.
33. Stanley WC. Rationale for a metabolic approch in diabetic coronary patients. Coron Artery Dis 2005; 16 (supp. 1): S11–5.
34. Петрий В.В., Микова Н.В., Маколкин В.И. Коррекция триметазидином МВ эпизодов преходящей ишемии миокарда у больных ишемической болезнью сердца в сочетании с сахарным диабетом 2-го типа. Кардиология. 2007; 7: 22–5.
35. El-Kady Т, El-Sabban K, Gabaly M et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunction myocardium in ischemic cardiopathy: a 24-month study. Am J Cardiovasc Drugs 2005; 5 (4): 271–8.
36. Belardinelli R. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy. Rev Port Cardiol 2000; 19 (suppl. 5): V35–9.
37. Маколкин В.И. Ишемическая дисфункция миокарда и пути ее коррекции. Форум. Ишемич. бол. сердца. 2000; 2: 2–4.
38. Bertomeu-Gonzalez V, Burgas-Mosquera A, Kaski JC. Role of trimetazidine in management of ischemic cardiomyopathy. Am J Cardiol 2006; 98 (suppl.): 9J–24.
39. Timour Q, Harpey C, Durr F et al. Is the antianginal action of trimetazidine independent of hemodinamical changes? Cardiovasc Drugs Ther 1991; 5: 1043–4.
40. Sellier P, Audouin P, Payen B et al. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol 1987; 33: 205–7.
41. Lu C, Dabrowski P, Fragasso G et al. Effects of trimetazidine on ichemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898–901.
42. Michaelides AP, Vyssoulis GR, Bonoris PE et al. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr Ther Res 1989; 46: 565–76.
43. Passeron J. Efficacitй de la trimйtazidine dans I'angor d'effort stable de l'insuffisant coronarien chronique. Etude а double insu contre placebo. Presse Med 1986; 15: 1775–8.
44. Dalla-Volta S, Maraglino G, Della-Valentina P et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. J Cardiovasc Drugs Ther 1990; 4 (suppl. 4): 853–9.
45. Аронов Д.М., Тартаковский Л.Б., Новикова Н.К. и др. Сравнительная оценка влияния физических тренировок и триметазидина на динамику ишемии миокарда и показатели физической работоспособности больных ишемической болезнью сердца. Кардиоваск. тер. и проф. 2002; 4: 32–40.
46. Belardinelli R, Lacalaprice F, Faccenda E, Volpe L. Clinical benefits a metabolic approach in the cardiac rehabilitation of patients with coronary artery disease. Am J Cardiol 2006; 98 (suppl.): 25J–33.